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INTERFERON-BASED CYTOKINE THERAPY FOR 
ADV ANCED RENAL CELL CARCINOMA 
Tatsuya TAKAYAMA， Fumitake KAI， Takayuki SUGIYAMA， 
Hiroshi FURUSE， Soichi MUGIYA and Seiichiro OZONO 
The Department 01 Urology， Hamamatsu UniversiりSchool01 Medicine 
Among 126 patients diagnosed with metastatic renal cel carcinoma at Hamamatsu University or 
its affiliated hospital between 1978 and 2004， pretreatment features associated with a shorter survival in 
the multivariate analysis were in symptomatic status at diagnosis and in multiple organ metastasis. 
The 1・and3-year survival rate in patients with these two prognostic factors were 22.3 and 0.3%， 
respectively. The style of treatment did not influenced survival in these patients. Therefore， an 
accurate assessment oftheir survival benefits both them and physician while it is urgent that we develop 
novel agents and strategy. 
(Hinyokika Kiyo 51 : 499-502， 2005) 

































が20例，症候癌が106例で， growing typeはslowtype 
が24例， rapid typeが100例，不明2例であった.PS 
は， 0 -1が102例， 2以上が24例であった.治療法
は，腎摘除術のみが18例，腎摘除術+サイトカイン療
法が77例で，その内訳は IFNα:42例， IFNα+IL2: 
10例， IFNα+インターフエロン y(IFNy) : 19例，



































































No. of metastatic site 
Lung metastasis 
* Two and four patients are missing date on growing type and hemoglobin， respectively. 
Prognostic factors for cause-specific survival by multivariate analysis (Cox's proportional hazard 
model) 























0.3799 0.756-2.083 1.255 82/ 40 Hemoglobin* (mg/dl) 










* Two and four patients are missing date on growing type and hemoglobin， respectively. 
Nx(+) +eytokioe: n = 77 
Nx(う+cytokioe:0 = 15 
Nx(+): 0 = 18 
00 treatmeot : 0= 16 
Nx(+) +cytokioe vs. Nxや)+cytokioe: p = 0.2085 
Nx(+) +cytokine vs. Nx(+) : p =0.0051 
Nx(+) +cytokine vs. no treatmeot: p = 0.0026 









9 345 6 
Years from diagnosis 
Survival curves stratified according to treatment. 














0， 1， 2個で群別してみると， 2つの因子をともに
有する群 (n=38)では生存率は明らかに低く， 1， 3 
年生存率は22.3，0.3%であった. 6年以上にわたり
長期生存している l例を除けば，残り37例はすべて2
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1 risk factor: 0 = 72 
2 risk factors: 0 = 38 
O~ι1: p =0.0358 
1 ~ι2: p<0.OO01 






た (Table2). Motzerらは Karnotskyperformance 
statusが80%未満，補正 Caが 10mg/dlより高値，










上の長期生存が得られている l例 (slowgrowing type 
234 5 6 7 8 9 
Yea陪 fromdiagnosis 




N豆(・)+句rtokioe:0 = 6 
Nx(+): 0=4 
00 tr回t阻eot:0 =8 
Not significant among each group 
o 2 345 6 7 
Years from diagnosis 
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